Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Neurology

Amyotrophic lateral sclerosis (ALS); Parkinson's disease (PD)

Superoxide dismutase 1 (SOD1)

Mouse and worm studies suggest a new class of carbazoles could help treat ALS and PD. Previous work identified a lead aminopropylcarbazole that prevented apoptosis of hippocampal neurons in newborn mice. In a mutant SOD1 mouse model of ALS, an optimized aminopropylcarbazole increased survival of spinal motor neurons, delayed disease onset and decreased loss of motor function compared with vehicle. In mouse and Caenorhabditis elegans models of chemically induced PD, the optimized carbazole increased survival of dopaminergic neurons compared with vehicle. Ongoing work in collaboration with 2M BioTech L.P. includes testing the aminopropylcarbazoles in models of traumatic brain injury and peripheral nerve injury.

SciBX 5(40); doi:10.1038/scibx.2012.1059
Published online Oct. 11, 2012

Patented by The University of Texas System and 2M Biotech; available for licensing or partnering

De Jesús-Cortés, H. et al. Proc. Natl. Acad. Sci. USA; published online
Oct. 1, 2012;
doi:10.1073/pnas.1213956109
Tesla, R. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 1, 2012;
doi:10.1073/pnas.1213960109
Contact: Andrew A. Pieper, University of Iowa Carver College of Medicine, Iowa City, Iowa
e-mail:
andrew-pieper@uiowa.edu

Contact: Steven L. McKnight,
The University of Texas Southwestern Medical Center, Dallas, Texas
e-mail:
steven.mcknight@utsouthwestern.edu

Contact: Joseph M. Ready,
same affiliation as above
e-mail:
joseph.ready@utsouthwestern.edu